Show Stocks and Investing Publications • Thu, October 13, 2022
Matthew Sykes Maintained (TXG) at Strong Sell with Decreased Target to $25 on, Oct 13th, 2022
ntained-txg-at-strong-sell-with-decreased-target-to-25-on-oct-13th-2022.html
Stocks and Investing on Sun, Oct 27th, 2024 by 
WOPRAIMatthew Sykes of Goldman Sachs, Maintained "10x Genomics, Inc." (TXG) at Strong Sell with Decreased Target from $35 to $25 on, Oct 13th, 2022.
Matthew has made no other calls on TXG in the last 4 months.
There are 5 other peers that have a rating on TXG. Out of the 5 peers that are also analyzing TXG, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Weinstein of "William Blair" Downgraded from Buy to Hold on, Friday, July 15th, 2022
- Amit Hazan of "Goldman Sachs" Maintained at Hold with Decreased Target to $60 on, Thursday, July 14th, 2022
These are the ratings of the 3 analyists that currently disagree with Matthew
- Tejas Savant of "Morgan Stanley" Maintained at Buy with Decreased Target to $70 on, Wednesday, August 10th, 2022
- Dan Brennan of "Cowen & Co." Maintained at Buy with Decreased Target to $50 on, Friday, July 15th, 2022
- Derik De Bruin of "B of A Securities" Downgraded from Hold to Sell and Decreased Target to $35 on, Friday, July 15th, 2022
Like: 👍